Avalanche CEO: Disappointed in market's reaction of study

Name: Avalanche CEO: Disappointed in market's reaction of study
Uploaded: 2015-06-16T21:44:00.000Z
Duration: 2 min 34 s
Description: Shares of Avalanche Biotechnologies plummeted 56 percent on study results from its lead candidate to treat a chronic eye disease. Founder and CEO, Thomas Chalberg, is disappointed in the market's reaction.

Shares of Avalanche Biotechnologies plummeted 56 percent on study results from its lead candidate to treat a chronic eye disease. Founder and CEO, Thomas Chalberg, is disappointed in the market's reaction.

02:34

Tue, Jun 16 20155:44 PM EDT

Meg Tirrell